Plasminogen — Drug Target
All drugs that target Plasminogen — marketed and clinical-stage. Includes 9 drug classes acting on this target.
Drug classes
Fibrinolytic agent / Tissue plasminogen activator (tPA) · Antifibrinolytic Agent · Antifibrinolytic Agent [EPC] · Fibrinolytic agent / Thrombolytic · Thrombolytic · Fibrinolytic agent · Thrombolytic agent · Fibrinolytic agent / Plasminogen activator · Antifibrinolytic agent
Marketed (8)
- Activase · Roche · Cardiovascular
- alteplase dwell arm · University of Manitoba · Fibrinolytic agent / Tissue plasminogen activator (tPA) · Cardiovascular / Thromboembolism
Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin to dissolve blood clots. - Trasylol · Bayer · Antifibrinolytic Agent · Hematology
- Cyklokapron · Exela Pharma · Antifibrinolytic Agent [EPC] · Cardiovascular
Tranexamic acid works by binding to plasminogen and preventing its conversion to plasmin, thereby inhibiting fibrinolysis. - Amicar · Epic Pharma Llc · Antifibrinolytic Agent [EPC] · Cardiovascular
- Cathflo Activase (Alteplase) · Genentech, Inc. · Fibrinolytic agent / Tissue plasminogen activator (tPA) · Cardiovascular / Interventional
Alteplase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots. - Recombinant Staphylokinase · The First Affiliated Hospital with Nanjing Medical University · Fibrinolytic agent / Thrombolytic · Cardiovascular
Recombinant staphylokinase is a fibrinolytic enzyme that directly activates plasminogen to plasmin, dissolving blood clots. - Recombinant Streptokinase · Beijing Chao Yang Hospital · Fibrinolytic agent / Thrombolytic · Cardiovascular
Recombinant streptokinase is a fibrinolytic enzyme that activates plasminogen to plasmin, dissolving blood clots by breaking down fibrin.
Phase 3 pipeline (11)
- Recombinant human urokinase · Tasly Biopharmaceuticals Co., Ltd. · Thrombolytic · Cardiovascular
Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots. - Urokinase thrombolysis · Capital Medical University · Fibrinolytic agent · Cardiovascular
Urokinase thrombolysis works by activating plasminogen to plasmin, which breaks down blood clots. - r-tPA · Thrombolex, Inc. · Fibrinolytic agent / Thrombolytic · Cardiovascular
r-tPA is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow. - Metalyse · AO GENERIUM · Other
- Amchafibrin · Fundación Pública Andaluza Progreso y Salud · Rare Disease
- transamin · Erzincan Military Hospital · Rare Disease
- Low-dose rtPA · The George Institute · Thrombolytic agent · Cardiovascular
Low-dose rtPA is a thrombolytic agent that activates plasminogen to dissolve blood clots by converting it to plasmin. - non-immunogenic staphylokinase · Supergene, LLC · Fibrinolytic agent · Cardiovascular
Non-immunogenic staphylokinase is a genetically engineered enzyme that catalyzes the conversion of plasminogen to plasmin, thereby dissolving blood clots. - Intravenous rhPro-UK · First Affiliated Hospital Xi'an Jiaotong University · Thrombolytic agent · Cardiovascular
Recombinant human prourokinase (rhPro-UK) is a thrombolytic agent that converts plasminogen to plasmin, dissolving blood clots. - Non-immunogenic recombinant staphylokinase · Supergene, LLC · Fibrinolytic agent / Plasminogen activator · Cardiovascular
Non-immunogenic recombinant staphylokinase is a fibrinolytic enzyme that directly activates plasminogen to plasmin, dissolving blood clots without triggering immune responses. - No tranexamic acid · Sunnybrook Health Sciences Centre · Antifibrinolytic agent · Hematology / Hemostasis
Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, reducing fibrin degradation and promoting blood clot stability.
Phase 2 pipeline (1)
- Human Plasminogen · Kedrion S.p.A. · Fibrinolytic agent · Cardiovascular
Activates plasminogen to break down blood clots